<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methamphetamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01577</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit</td></tr><tr><th>Description</th><td><p>Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01577/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01577/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01577.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01577.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01577.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01577.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01577.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01577">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+)-(S)-N-&#945;-dimethylphenethylamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(S)-N,&#945;-dimethylbenzeneethanamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(&#945;S)-N,&#945;-dimethylbenzeneethanamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>d-1-phenyl-2-methylaminopropane</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>d-deoxyephedrine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>d-desoxyephedrine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>d-N-methylamphetamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>d-phenylisopropylmethylamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>M&#233;tamf&#233;tamine</td><td>French</td><td>INN</td></tr><tr><td>Metamfetaminum</td><td>Latin</td><td>INN</td></tr><tr><td>Metanfetamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Methamphetaminum</td><td>Latin</td><td>INN</td></tr><tr><td>methyl-&#946;-phenylisopropylamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methamphetamine hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000734/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000734/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: MYWUZJCMWCOHBA-VIFPVBQESA-N</li>
              <li>Monoisotopic Mass: 149.120449485</li>
              <li>Average Mass: 149.2328</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000734">DBSALT000734</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Desoxyn</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adrenergic-agents">Adrenergic Agents</a></li>
<li><a href="/mesh/adrenergic-uptake-inhibitors">Adrenergic Uptake Inhibitors</a></li>
<li><a href="/mesh/central-nervous-system-stimulants">Central Nervous System Stimulants</a></li>
<li><a href="/mesh/dopamine-agents">Dopamine Agents</a></li>
<li><a href="/mesh/dopamine-uptake-inhibitors">Dopamine Uptake Inhibitors</a></li>
<li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li></ul></td></tr><tr><th>CAS number</th><td>537-46-2</td></tr><tr><th>Weight</th><td>Average: 149.2328<br>Monoisotopic: 149.120449485</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>15</sub>N</td></tr><tr><th>InChI Key</th><td>MYWUZJCMWCOHBA-VIFPVBQESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">methyl[(2S)-1-phenylpropan-2-yl]amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN[C@@H](C)CC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01577.gif?1265922772">show</a>(2.96 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>polyamine; secondary aliphatic amine; secondary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.</td></tr><tr><th>Pharmacodynamics</th><td>Methamphetamine is a potent central nervous system stimulant which affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. The acute effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite. </td></tr><tr><th>Mechanism of action</th><td>Methamphetamine enters the brain and triggers a cascading release of norepinephrine, dopamine and serotonin. To a lesser extent methamphetamine acts as a dopaminergic and adrenergic reuptake inhibitor and in high concentrations as a monamine oxidase inhibitor (MAOI). The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown.</td></tr><tr><th>Absorption</th><td>Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine, with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine. Other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Methamphetamine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00540">Norephedrine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/557">Details</a></td></tr><tr><td>Methamphetamine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00733">4-hydroxyamphetamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/754">Details</a></td></tr><tr><td>Methamphetamine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00735">4-hydroxymethamphetamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/756">Details</a></td></tr><tr><td>Methamphetamine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01018">4-Hydroxynorephedrine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1041">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.</td></tr><tr><th>Half life</th><td>The biological half-life has been reported in the range of 4 to 5 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Manifestations of acute overdosage with methamphetamine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>PRKCA-binding protein<br>Gene symbol: PICK1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9NRD5" target="_blank">Q9NRD5 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs713729" target="_blank">rs713729 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T allele</td><td>Methamphetamine psychosis and addiction</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17606663" target="_blank" title="Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M: Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul;164(7):1105-14.">17606663 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>PRKCA-binding protein<br>Gene symbol: PICK1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9NRD5" target="_blank">Q9NRD5 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2076369" target="_blank">rs2076369 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G allele</td><td>Methamphetamine psychosis and addiction</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17606663" target="_blank" title="Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M: Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul;164(7):1105-14.">17606663 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.993</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9695</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8675</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6682</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9338</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9816</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.736</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6771</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.957</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8695</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7754</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9536</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9095</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9306
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8161
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7508
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1862 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9443
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9118
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Lundbeck inc</li>
<li>Able laboratories inc</li>
<li>Coastal pharmaceuticals inc</li>
<li>Rexar pharmacal</li>
<li>Teva pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.chattem.com">Chattem Chemicals Inc.</a></li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Decreased anorexic effect, may increases psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00623">Fluphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Methamphetamine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01608">Propericiazine</a></td><td>Decreased anorexic effect, may increase pyschotic symptoms</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Methamphetamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Methamphetamine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Methamphetamine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Methamphetamine. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine may reduce the sedative effect of the antihistamine, Methamphetamine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>